EUCTR2004-001263-22-EE进行中（未招募）不适用
A Phase III study of DPPE (Temilifene) combined with Epirubicin and Cyclophosphamide versus Epirubicin and Cyclophosphamide alone as First – line Treatment in Metastatic/Recurrent Cancer - The DEC Trial
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Histological proof of breast cancer
- •2.Documented evidence of metastatic and/or recurrent breast cancer. Patients with locally advanced and inoperable lesions are also eligible
- •3.Imaging within 21 days prior randomization. Exceptions will be made only for patients who have had negative examinations within 35 days prior to randomization
- •4.Presence of at least one uni-dimensional measurable lesion.
- •a.If the patient’s only lesion(s) have been irradiated, progression in the site(s) following radiotherapy must have occurred.
- •b.Minimum indicator lesion size must be as follows: CT scan > 2 cm; Ultrasound > 2 cm; Chest x-ray > 1 cm; skin lesion or node > 1 cm
- •5.Previous therapy
- •a.Anti-hormonal: if patients have had hormone-responsive disease, randomization is permitted after 6 weeks off anti-hormonal therapy unless there is evidence of
- •progressive disease in which case patients will be randomized earlier. All hormonal therapy must be discontinued prior to randomization
- •b.Chemotherapy: patients may have had one adjuvant chemotherapy regimen with the following restrictions:
- •i.no previous exposure to anthracycline/anthracenedione-based chemotherapy (doxorubicin, epirubicin, or mitoxantrone),
- •ii.if received non-anthracycline based adjuvant chemotherapy, it should completed a minimum of 4 weeks prior to randomization.
- •iii.No previous chemotherapy for metastatic disease permitted.
- •iv.Immunotherapy and experimental therapy should be stopped a minimum of 4 weeks prior to randomization
- •c.Radiation: should be stopped a minimum of 4 weeks prior randomization, with the exemption of palliative radiotherapy
- •6.ECOG performance status 0, 1 or 2
- •7.Age > 16 years (the minimum age limit may be determined by the local center’s policies regarding the age at which an individual may sign their own informed consent)
- •8.Able to complete baseline and follow up Quality of Life questionnaires
- •9.Acceptable Hematology and Chemistry results
- •10.MUGA scan showing LVEF ? 50% (within 21 days of randomization)
- •11.Patient must sign an Inform Consent Form prior to randomization
- •12.Patient must be accessible for treatment and follow up at the same center as where randomized
- •13.Protocol treatment is to begin within 5 working days of randomization
- •14.Disease free interval (DFI) less than or equal to 36 months
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Previous malignancy, excluding curatively treated basal or squamous cell carcinoma of the skin or in situ cervical cancer or any other cancer treated more than five years prior to study entry (presumed cured).
- •2.Patients with brain or meningeal metastases
- •3.Patients whose only measurable disease is in bone
- •4.Patients with clinical evidence of congestive heart failure (CHF), recent myocardial infarction within 6 months, uncontrolled arterial hypertension, unstable angina, cardiomyopathy or atrial or ventricular arrhythmias even if medically controlled
- •5.Patients with any history of seizure disorder
- •6.Patients with other serious illnesses or medical conditions, including clinically significant or uncontrolled inflammation or infectious disease, which would not permit the patient to be managed according to the protocol.
- •7.Pregnant or breast-feeding females. All women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to randomization
- •8.Patients on COX 1 or 2 prostaglandin inhibitors (e.g. ASA, Celebrex) must comply with guidelines within the protocol for concomitant therapy
- •9.Patients on H1 antagonists (e.g. antihistamines or antidepressants) that cannot be discontinued during their time on study
研究者
相似试验
进行中（未招募）
1 期
Phase III Trial Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx®, Doxil®) for Women (age 66 years or older) with Endocrine Nonresponsive Breast Cancer Who Are NOT Suitable for Being Offered a Standard Chemotherapy Regimen” - Chemotherapy Adjuvant Study for women at advanced Age (CASA)Older women (66 years of age or older) with histologically proven, resected breast cancer. The disease must be classified as endocrine nonresponsive and patients must not be candidates for endocrine therapy or for an adjuvant chemotherapy program which includes a standard” anthracycline-containing chemotherapy regimen.MedDRA version: 8.1Level: LLTClassification code 10006188Term: Breast cancer female NOSEUCTR2005-003434-18-FRInternational Breast Cancer Study Group (IBCSG)77
已完成
3 期
IBCSG 32-05 / BIG 1-05 - Chemotherapy Adjuvant Study for women at advanced ageCancer - BreastBreast CancerACTRN12606000077561Australian New Zealand Breast Cancer Trials Group1,296
进行中（未招募）
1 期
Phase III Trial Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin PLD, Caelyx, Doxil for Women age 66 years or older with Endocrine Nonresponsive Breast Cancer Who Are NOT Suitable for Being Offered a Standard Chemotherapy RegimenEUCTR2005-003434-18-ITIBCSG77
进行中（未招募）
不适用
Phase III Trial Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx®, Doxil®) for Women (age 66 years or older) with Endocrine Nonresponsive Breast Cancer Who Are NOT Suitable for Being Offered a Standard Chemotherapy Regimen” - Chemotherapy Adjuvant Study for women at advanced Age (CASA)Older women (66 years of age or older) with histologically proven, resected breast cancer. The disease must be classified as endocrine nonresponsive and patients must not be candidates for endocrine therapy or for an adjuvant chemotherapy program which includes a standard” anthracycline-containing chemotherapy regimen.MedDRA version: 8.1Level: LLTClassification code 10006188Term: Breast cancer female NOSEUCTR2005-003434-18-BEInternational Breast Cancer Study Group (IBCSG)1,296
进行中（未招募）
1 期
A Phase III Study to Evaluate Chemotherapy With or Without Pembrolizumab as First Line Treatment for Triple Negative Breast CancerTriple-Negative Breast CancerEUCTR2016-001432-35-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.858